Nuklearmedizin. Nuclear medicine最新文献

{"title":"McCune-Albright Syndrome with Extensive Fibrous Dysplasia Evaluated by 18F-FDG PET/CT and Whole-body Bone Scintigraphy: A Case Report.","authors":"Taiping Liao, Guoxu Fu, Yongjun Long, Li Li, Qinling Qi, Lingxiao Li","doi":"10.1055/a-2843-4797","DOIUrl":"10.1055/a-2843-4797","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"271-274"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"False-Positive Rib Lesion on Bone Scintigraphy and 68Ga-PSMA PET/CT: Fibrous Dysplasia Mimicking Metastasis.","authors":"Muhammet Halil Baltacioglu","doi":"10.1055/a-2843-4897","DOIUrl":"10.1055/a-2843-4897","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"278-279"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary gallbladder metastases by malignant melanoma.","authors":"Marcel Baehr, Yenny Angela, Raihanatou Diallo-Danebrock, Jan Borggrefe, Alexey Surov","doi":"10.1055/a-2857-7719","DOIUrl":"10.1055/a-2857-7719","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"280-281"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab.","authors":"Joana do Mar Ferreira Machado, Kristof Zarschler, Torsten Knieß, Martin Kreller, Matthias Miederer, Florian Brandt, Rudi Apolle, Theresa Link, Robert Winzer, Pauline Wimberger, Klaus Kopka, Oliver Kiß","doi":"10.1055/a-2883-7600","DOIUrl":"10.1055/a-2883-7600","url":null,"abstract":"<p><strong>Aim: </strong>[⁸⁹Zr]Zr-DFO-trastuzumab has emerged as a powerful tool to visualise non-invasively HER2 expression across metastatic lesions, complementing conventional pathological HER2 evaluation and helping to identify patients unlikely to benefit from therapy with trastuzumab-based therapies. This paper outlines the roadmap of the manufacturing implementation of [⁸⁹Zr]Zr-DFO-trastuzumab at our centre in Germany.</p><p><strong>Methods: </strong>In this paper, we describe the key questions encountered during implementation of the manufacturing process for [⁸⁹Zr]Zr-DFO-trastuzumab and how these were addressed through discussions between academia, hospital departments, teams experienced in the radiolabelling of antibodies and regulatory authorities.</p><p><strong>Results: </strong>Discussions with multiple institutions were essential for the implementation of the GMP-compliant radiosynthesis of [⁸⁹Zr]Zr-DFO-trastuzumab at our manufacturing site. Example decisions included shortening the shelf-life of [⁸⁹Zr]Zr-DFO-trastuzumab to 24 hours to mitigate container-closure integrity concerns and adoption of a bead-based method to determine the immunoreactive fraction.</p><p><strong>Conclusion: </strong>This work presents a practical overview of operational considerations relevant to the clinical implementation of [⁸⁹Zr]Zr-DFO-trastuzumab, with potential applicability to other ⁸⁹Zr-labelled high-molecular-weight radiotracers in Germany. By sharing these practical insights, we aim to support broader patient access to established radiopharmaceuticals and encourage dialogue around open regulatory and practical questions, particularly in anticipation of future clinical trials.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"265-270"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-exprimierende Nebennierenläsion beim Prostatakarzinom: Phäochromozytom statt Metastase.","authors":"Anna Kisters, Haissam Ragab, Natalia Gorbokon, Amir Karimzadeh","doi":"10.1055/a-2890-8413","DOIUrl":"10.1055/a-2890-8413","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"275-277"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DGN procedural guideline for bone scintigraphy with SPECT and SPECT/CT in children and adolescents.","authors":"J M M Rogasch, H Amthauer, R Kluge, R Bares, I Schatka, T Pfluger, C Franzius","doi":"10.1055/a-2784-7659","DOIUrl":"10.1055/a-2784-7659","url":null,"abstract":"<p><strong>Abstract: </strong>AIM: To present the updated S1 guideline recommendations on bone scintigraphy, including SPECT and SPECT/CT, in children and adolescents, with a particular focus on its positioning relative to alternative imaging modalities and on optimization of radiation protection.</p><p><strong>Abstract: </strong>METHODS: Narrative literature review and evaluation of interdisciplinary national and international guidelines, combined with expert consensus within the German Society of Nuclear Medicine. Indications, dosimetry and CT protocols were revised based on EANM recommendations, ICRP Publication 128 and newly established diagnostic reference levels.</p><p><strong>Abstract: </strong>RESULTS: Compared with the 2015 version, the clinical indications were comprehensively re-evaluated and restructured, with explicit consideration particularly of MRI and FDG-PET/CT or PET/MRI. Potential drug interactions relevant to image interpretation are listed systematically. Radiation exposure data were updated according to ICRP 128. For SPECT/CT, detailed age- and diameter-adapted recommendations for low-dose CT dose reduction were formulated. In addition, the role of [¹⁸F]NaF PET as a potential alternative to conventional bone scintigraphy in childhood is described.</p><p><strong>Abstract: </strong>CONCLUSIONS: The updated guideline refines and sharpens the indications for bone scintigraphy in the context of MRI and PET techniques and reinforces the use of radiation dose-optimized protocols. It supports nuclear medicine teams in evidence- and guideline-based imaging of paediatric skeletal disorders.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"240-254"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the utility of ChatGPT in conducting a literature review on deep learning for dopamine transporter SPECT with [¹²³I]ioflupane.","authors":"Thomas Buddenkotte, Ivayla Ilieva Apostolova, Roland Opfer, Susanne Klutmann, Rickmer Braren, Henning Boecker, Ralph Buchert","doi":"10.1055/a-2890-8325","DOIUrl":"10.1055/a-2890-8325","url":null,"abstract":"<p><strong>Aim: </strong>This study evaluated ChatGPT (GPT-5.2) for drafting a review paper on deep learning in dopamine transporter (DAT)-SPECT with [¹²³I]ioflupane.</p><p><strong>Methods: </strong>The review workflow consisted of 3 steps: (i) literature search, (ii) generation of structured summaries with 24 predefined fields for each publication, and (iii) drafting a review paper based on the structured summaries across all publications. A detailed prompt for ChatGPT was iteratively designed for each step with ChatGPT support. A manual literature search was independently performed by an expert in DAT-SPECT and deep learning. ChatGPT-generated structured summaries were manually fact-checked against the full publications and corrected where necessary. The review draft generated by ChatGPT was checked against the corrected summaries.</p><p><strong>Results: </strong>When prompted to compile an exhaustive list of publications, ChatGPT cited 13 papers, whereas the manual search identified 70 relevant publications, 67 of which were included. Corrections to ChatGPT-generated structured summaries were required in 27 cases (40.3%), affecting one or two of the 24 predefined fields, while no changes were necessary in 40 publications (59.7%). Most corrections could likely have been avoided by more precise prompting. All numerical information (dataset sizes, train-test splits, performance metrics) was correct. The review draft (~950 words) generated by ChatGPT was content-wise meaningful and accurate, but contained referencing errors, including incorrect citations, missing references, and citations of non-existent publications.</p><p><strong>Conclusions: </strong>ChatGPT is a highly effective tool for drafting review manuscripts in nuclear medicine imaging, but its limitations in literature retrieval and referencing require careful expert supervision.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"255-264"},"PeriodicalIF":1.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"German Society of Nuclear Medicine procedure guideline for dopamine transporter SPECT using [123I]ioflupane (02/2026).","authors":"Ralph Buchert, Nathalie L Albert, Henryk Barthel, Henning Boecker, Caroline Bouter, Matthias Brendel, Joachim Brumberg, Alexander Drzezga, Gerhard Gründer, Swen Hesse, Christian la Fougère, Catharina Lange, Philipp Lohmann, Isabelle Miederer, Bernd Neumaier, Axel Rominger, Mathias Schreckenberger, Igor Yakushev, Thilo van Eimeren, Philipp T Meyer","doi":"10.1055/a-2883-7728","DOIUrl":"https://doi.org/10.1055/a-2883-7728","url":null,"abstract":"<p><strong>Summary: </strong>This procedure guideline for SPECT examinations of striatal dopamine transporter availability is intended to support the planning, execution, quality control, interpretation and reporting of cerebral SPECT scans with [¹²³I]ioflupane. It is an update and expansion built on the 2019 version of the procedure guideline. It was developed through an informal process as a consensus of the Neuroimaging Working Group of the German Society of Nuclear Medicine and in consultation with the German Neurological Society. It is intended for use by physicians and technical staff working in the field of nuclear medicine.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.","authors":"Aleksei Leontev, Angelina Lokhova, Aleksandr Khalimon, Malika Khodzhibekova, Tatyana Lazutina, Gulnara Khamadeeva, Daria Khodakova, Irina Pylova, Vitaly Bobrov, Leila Atakishieva, Natalia Kadymova, Anastasia Nikiforuk, Bogdan Shvets, Nadezhda Volchenko, Viktoriya Surkova, Petr Shatalov, Andrey Kaprin","doi":"10.1055/a-2777-2278","DOIUrl":"10.1055/a-2777-2278","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to assess the impact of [¹⁸F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based (RC-based) correction of semi-quantitative and volume-based PET metrics.</p><p><strong>Methods: </strong>A retrospective multi-center study included 63 patients diagnosed with lung adenocarcinoma who underwent [¹⁸F]FDG PET/CT. Acquisition was performed according to the EANM guidelines using two EARL-accredited PET/CT-systems. All patients were divided into an EGFR-mutant (n=30) and a wild-type (n=33) groups based on the results of molecular testing. Maximal diameter and CT volume of each primary tumor lesion were measured. [¹⁸F]FDG uptake was evaluated by measurement of semi-quantitative and volume-based PET metrics such as SUVmax, SUVpeak, MTV, and TLG. TLG was measured using PET segmentation method by 3D-Isocontour tool with a 41% of SUVmax threshold (TLG_41%) and a threshold adapted to the CT volume (TLG_CT). Additionally, TLR was calculated as the ratio of tumor SUVpeak to liver SUVmean. Acquisition data of the NEMA IEC Body Phantom Set NU2-2018 were applied for plotting the RC curves which were used for following RC-based correction of PET metrics.</p><p><strong>Results: </strong>No significant difference in tumor lesion maximal diameter, CT volume, evaluated values of PET metrics before and after RC-based correction was found between the EGFR-mutant and wild-type groups (p > 0.05).</p><p><strong>Conclusion: </strong>Observed semi-quantitative and volume-based PET metrics obtained from [¹⁸F]FDG PET/CT have no significant value for predicting EGFR gene mutation status in patients with lung adenocarcinoma, regardless of whether RC-based correction is applied.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"199-206"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline FDG PET/CT-Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer.","authors":"Mehmet Tarık Tatoğlu, İlker Nihat Ökten, Ebru Ibisoglu, Tuçe Söylemez Akkurt, Ferda Yerdelen Tatoğlu, Hatice Uslu, Hakan Baysal","doi":"10.1055/a-2825-4883","DOIUrl":"10.1055/a-2825-4883","url":null,"abstract":"<p><strong>Aim: </strong>Predicting axillary pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) may enable risk-adapted axillary management in clinically node-positive breast cancer (BC), but practical baseline PET-derived predictors are limited.</p><p><strong>Methods: </strong>Single-center retrospective cohort of consecutive cN+, M0 patients with baseline [¹⁸F]FDG PET/CT-reported axillary nodal metastasis treated with NST and surgery (complete-case n=115). Axillary pCR was defined as no residual invasive carcinoma in axillary lymph nodes; isolated tumor cells and/or micrometastases were classified as non-pCR. Two prespecified ridge-penalized logistic models combined routine clinical variables with baseline PET-defined axillary burden as (i) hypermetabolic ALN count (Model A) or (ii) limited (1-3) versus advanced (≥4) burden group (Model B). Stratified 5-fold cross-validation generated out-of-fold (OOF) predictions; AUC, Brier score, and logistic recalibration slope/intercept were bootstrapped on OOF predictions (2000 resamples).</p><p><strong>Results: </strong>Axillary pCR occurred in 59/115 (51.3%). Discrimination was good: AUC 0.80 (95% CI 0.72-0.88) for Model A and 0.79 (95% CI 0.71-0.87) for Model B. Calibration was acceptable (bootstrap-mean slope/intercept ≈1.10/0.04 and 1.08/0.03, respectively). Greater baseline PET-defined axillary extent was associated with lower odds of pCR; molecular subtype and neoadjuvant anti-HER2 therapy remained strongly associated with response.</p><p><strong>Conclusion: </strong>Prespecified ridge models combining routine clinical variables with baseline [¹⁸F]FDG PET/CT-defined axillary burden showed good internal performance for predicting axillary pCR. External validation is required before response-adapted clinical use.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"65 3","pages":"207-216"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147990517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}